Full-Time

Counsel 2

Omnicell

Omnicell

1,001-5,000 employees

Medication management and pharmacy automation platform

No salary listed

Dallas, TX, USA + 2 more

More locations: Pittsburgh, PA, USA | Atlanta, GA, USA

Hybrid

Some travel (~10%) required.

Category
Legal & Compliance (2)
,
Required Skills
Data Governance
Requirements
  • J.D.; member in good standing of a state Bar
  • CIPP/US or CIPP/E (both preferred)
  • 5+ years of experience in either a law firm or in-house legal department providing counsel on data privacy, cybersecurity, and AI regulations, including regulatory compliance, complex data or technology transactions, and incident response
  • Substantial experience collaborating with cross-functional teams including IT, security, engineering, and compliance
  • Strong initiative and willingness to learn and develop new skills
  • Ability to identify complex legal and regulatory issues and offer pragmatic, actionable solutions
  • Deep understanding of privacy laws and cybersecurity regulatory frameworks
  • Knowledge of AI governance principles and emerging AI regulations
  • Effective interpersonal and problem-solving skills
  • Strong contract negotiation skills with specific experience in data processing agreements, security terms, and technology transactions
  • Ability to translate complex technical and legal concepts for diverse audiences
  • Ability to independently set and communicate prioritized goals and timelines to internal stakeholders
  • Highly organized with strong attention to detail
Responsibilities
  • Develop, implement, and maintain privacy policies, procedures, and compliance programs in accordance with applicable global data protection laws
  • Monitor emerging legislation and regulatory guidance related to privacy, cybersecurity, and AI; assess impact on business operations and recommend compliance strategies
  • Formalize and maintain legal artifacts including policies, procedures, templates, playbooks, and guidance documents for privacy, cybersecurity, and AI governance
  • Support cybersecurity legal initiatives, including contract negotiations for security terms, incident response planning, regulatory breach notifications, and coordination with information security teams
  • Develop and advance Omnicell's AI governance framework, including conducting risk assessments and reviews for AI systems, ensuring compliance with emerging AI regulations, and implementing ethical AI principles
  • Conduct Data Protection Impact Assessments, Algorithmic Impact Assessments, and security risk assessments for new technologies, systems, and business initiatives
  • Provide strategic legal counsel on data governance initiatives, including data classification, retention, cross-border transfers, and data subject rights management
  • Coordinate incident response activities for data breaches and security incidents, including regulatory notifications and customer communications
  • Negotiate complex data and technology transactions, including data processing agreements, business associate agreements, security exhibits, and AI-related contractual provisions
  • Collaborate with training teams to develop and deliver data privacy, security, and AI governance training programs for employees and stakeholders
Desired Qualifications
  • CIPM, AIGP, or other relevant privacy/cybersecurity certifications
  • Healthcare industry experience
  • Knowledge of information security frameworks (NIST, ISO 27001, SOC 2)
  • Familiarity with AI/ML technologies and their legal implications
  • Experience with AI governance and emerging technology legal issues
  • Experience with regulatory examinations and audits

Omnicell provides medication management solutions and adherence tools for health systems and pharmacies, combining pharmacy automation devices with cloud-based software to automate dispensing, manage inventory, and support patient adherence. The products mix hardware and a cloud platform that coordinates dispensing, inventory control, and clinical data through dashboards and analytics. Compared with competitors, Omnicell emphasizes a cloud-first software approach with a clear path to software-as-a-service and a hybrid direct-plus-partner sales model for end-to-end pharmacy automation and data services. Its goal is to realize the Autonomous Pharmacy by using automation and intelligent services to improve pharmacy care and patient outcomes while building recurring revenue.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mountain View, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $310 million, with non-GAAP EBITDA of $45 million.
  • Titan XT shipments begin in H2 2026, unlocking a $2.5 billion replacement cycle.
  • Recurring revenue reached $680-700 million annualized guidance, supporting SaaS margin expansion.

What critics are saying

  • Titan XT contributes modest revenue in 2026, delaying replacement-cycle upside.
  • OmniSphere rolls out through 2027, leaving competitors time to displace Omnicell.
  • Tariffs add roughly $12 million in 2026 costs, compressing gross margins.

What makes Omnicell unique

  • Omnicell combines dispensing cabinets, RFID, and cloud software across hospital workflows.
  • Titan XT targets autonomous medication management, not isolated point solutions.
  • OmniSphere links inventory, EHR integration, and analytics into one platform.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Omnicell who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 5th, 2026
Omnicell's Titan XT cabinet launch divides analysts on $1.3B revenue outlook

Omnicell's analyst narrative centres on its Titan XT cabinet system and a potential hospital replacement cycle, though opinions diverge sharply on timing. The modelled fair value holds at $57.43 amid mixed price target revisions. BofA, Benchmark and KeyBanc have taken bullish stances, with KeyBanc upgrading to Overweight at $60, citing competitive wins and a cabinet refresh cycle. Conversely, Piper Sandler cut its target by $14, flagging execution and timing risks around the same Titan XT story. Omnicell issued Q1 2026 revenue guidance of $300 million to $310 million and full-year guidance of $1.215 billion to $1.255 billion. The company has launched Titan XT in the US, with international rollout expected later in 2026.

Yahoo Finance
Feb 28th, 2026
Omnicell targets $2.4B revenue by 2031 with shift to AI-driven pharmacy automation

Omnicell, Inc. is transitioning from hardware-driven revenue to a software and services model, aiming to double revenue from $1.18 billion to $2.4 billion by 2031, according to a bullish thesis on Danny's Substack. The company is expanding through strategic acquisitions like ANiGENT and developing its "Autonomous Pharmacy" vision using AI and robotics. The healthcare automation firm benefits from high switching costs, over 900 patents and a large installed base. Recurring revenue is approaching 50% of total revenue, with margins expected to expand from low teens to mid-20s. Bulls believe the market currently undervalues Omnicell as a hardware vendor, creating potential for significant rerating as it shifts towards healthcare IT, with shares trading at $38.61 as of 18 February.

Yahoo Finance
Feb 2nd, 2026
Omnicell beats Q3 revenue estimates by 5%, stock surges 64% since earnings report

Omnicell, a provider of medication management automation and adherence tools for healthcare systems and pharmacies, reported third-quarter revenues of $310.6 million, up 10% year on year and exceeding analysts' expectations by 5%. The company also beat earnings per share estimates. "We are pleased with the strong financial performance delivered in the third quarter," said Randall Lipps, Omnicell's chairman, president and chief executive officer. The stock has risen 64% since reporting results and currently trades at $48.49. The healthcare technology for providers sector faces mixed conditions, with opportunities from AI-driven tools and government digitisation incentives offset by challenges including long sales cycles, slow adoption rates, and tightening hospital budgets. The four companies tracked in this sector reported satisfactory third-quarter results overall, though share prices have declined 5.3% on average since earnings.

Specialty Pharmacy Continuum
Aug 18th, 2025
Texas Children's Hospital Adopts RFID for OR Med Management

This May, medication and supply management technology company Omnicell launched a new radio frequency identification (RFID)-enabled device to manage medications in the operating room.

StreetInsider
Mar 24th, 2025
Omnicell (OMCL) appoints Perry Genova as CTO

Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.